四环医药重点推荐3-医美行业需求企稳有拐点，预期带动四环新老产品增长 #医美25年获批3大新品全年业绩转正+26年医美加速创新药大幅减亏业绩3倍增长 行业需求： 1）大趋势有企稳迹象：近期调研华东多地反馈经过22-24年客流、零售价格双重承压下，12-1月客流呈现有好转 的态势，美莱、所调研精品机构均实现双位数客流增长。 2）零售价格鉴于人力、营销成本老品逐渐稳定；3）另外老客户 四环医药重点推荐3-医美行业需求企稳有拐点，预期带动四环新老产品增长 4）肉毒是第二大注射品类，目前行业出货量高单位数-低双位数增长，预计未来多年都有增长动能。 四环现有医美核心产品：1）肉毒素乐提葆；2）斯弗妍童颜针倾妍少女针；3）复合动能素冷妍；4）铂安润玻尿 酸；5）黑曜双波黄金微针。 行业需求： 1）大趋势有企稳迹象：近期调研华东多地反馈经过22-24年客流、零售价格双重承压下，12-1月客流呈现有好转 的态势，美莱、所调研精品机构均实现双位数客流增长。 2）零售价格鉴于人力、营销成本老品逐渐稳定；3）另外老客户消费有升级趋势，客单走高。 品类细分： 1）注射填充类玻尿酸有压力，但童颜针2025年因为更多定位中档的厂家获批出 ...

Core Viewpoint - Four Seasons Pharmaceutical has launched three self-developed aesthetic products, becoming the only compliant dual regeneration injection holder in China [1] Group 1: Product Launch and Innovation - The newly launched products include: 1) PLLA Youthful Injection, which is divided into two variants based on microsphere particle size: Sifuyan (larger particles for deep injection) and Huiyan Zhen (finer particles for dermal applications) [1] - 2) PCL Tinging, which features uniform particle size and high dispersion to avoid local irritation, enhancing support and viscoelasticity during injection [1] - The company is transitioning from single products to comprehensive aesthetic treatment solutions, addressing the evolving consumer demand for more complete aesthetic plans [1] Group 2: Market Position and Strategy - The core barriers for aesthetic enterprises lie in high-quality pipelines (underlying R&D capabilities) and B2B2C channel management (commercialization capabilities) [2] - Four Seasons Pharmaceutical has built a product matrix of over 60 products through self-research and business development, with its core product, Letibao Botulinum Toxin, covering over 6,200 aesthetic institutions across more than 370 cities in China [2] - The launch of the three regeneration products significantly strengthens the company's pipeline synergy, with expectations for performance growth through collaboration with existing products and mature channel systems [2] Group 3: Financial Performance and Forecast - The company is expected to achieve revenues of 2.32 billion, 3.44 billion, and 4.73 billion yuan in 2025-2027, with growth rates of 22%, 48%, and 37% respectively [2] - The net profit attributable to the parent company is projected to be 60 million, 530 million, and 780 million yuan for the same period, with a corresponding PE of 22 times for 2026 [2] - The adjustment in revenue forecasts reflects the strengthening of pipeline synergy and performance realization from the new aesthetic products [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% within the next six months [19]. Core Viewpoints - The launch of new regenerative products positions the company as the only compliant holder of dual regenerative injectables in China [2]. - The company is transitioning from single product offerings to comprehensive aesthetic treatment solutions, addressing the evolving demands in the aesthetic medicine market [4]. - The company has established a robust product pipeline and distribution network, with over 60 products developed and a presence in more than 6,200 aesthetic institutions across 370 cities [5]. - The traditional pharmaceutical business is stabilizing, with a focus on innovative drugs, including the upcoming launches of key products [6]. Financial Performance and Forecast - Revenue projections for 2025-2027 are adjusted to 2.32 billion, 3.44 billion, and 4.73 billion RMB, respectively, with growth rates of 22%, 48%, and 37% [6]. - The net profit forecast for the same period is 63 million, 528 million, and 783 million RMB, with corresponding growth rates of 129%, 736%, and 48% [6]. - The expected price-to-earnings ratio for 2026 is 22 times, reflecting a positive outlook on profitability [6].